AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
135.36
+0.14 (0.10%)
May 12, 2025, 4:00 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
54.98B
Revenue Growth
+15.48%
P/S Ratio
3.83
Revenue / Employee
583.05K
Employees
94,300
Market Cap
210.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
AstraZeneca News
- 20 hours ago - AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER - This is Money
- 1 day ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 1 day ago - Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%' - The Guardian
- 1 day ago - AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News - GuruFocus
- 4 days ago - AstraZeneca's bladder cancer treatment shows positive results in trial - Seeking Alpha
- 4 days ago - IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial - Business Wire
- 5 days ago - AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer - Seeking Alpha
- 6 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - Benzinga